Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
25% more patients experience an improvement in their asthma control with Relvar vs other commonly used ICS/LABAs*1
The Salford Lung Study (SLS) was a robust, open-label, pragmatic RCT comparing Relvar with usual care (ICS or ICS/LABA) in 4233 patients.1
At baseline, the most commonly prescribed ICS/LABAs were:2
This graph has been independently created by GSK from the original data. The same results were first published in Woodcock A, et al. Lancet 2017;390:2247–2255.
Looking at the individual aspects of the Asthma Control Test (ACT), Relvar treatment provides a higher mean change in symptom improvement from baseline vs other commonly prescribed ICS/LABAs.‡4